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Principles of haematopoietic transplantation
The terms ‘haematopoietic stem cell’ and ‘stem cell
transplantation’ have been defined by Little and Storb
(2002): “A primitive and immature cell of the haemato-
poietic system that has the capacity to give rise to all the
cells of the blood system, as well as the ability to self-
renew. Allogeneic haematopoietic stem cell transplantation
involves the transfer of both immature and mature blood
cells from the bone marrow, peripheral blood or cord
blood from one individual to another.” The first experi-
ences in haematopoietic transplantation have been made
in mice in the late 1940s and the early 1950s by Jacobson
et al. (1949) and Lorenz et al. (1951) in the wake of
the first atomic bomb explosions in Japan and its life-
threatening effects due to bone marrow failure. Since then,
every decade is featured by revolutionary developments.
Epigenetic approaches might be the discovery of the
2010s.
Indications for allogeneic haematopoietic transplantation
are both malignant and nonmalignant diseases; most of all
transplantations are administered for haematological malig-
nancies, e.g. acute and chronic leukaemias, myelodysplasia
and myeloproliferative disorders.
The procedure of allogeneic stem cell transplantation can
be divided into four main phases as summarized in Table 1.
In addition to irradiation and high-dose chemotherapy,
residual malignant cells are eliminated by the graft-versus-
leukaemia reaction (GvL). The beneficial effect of this
immunological mechanism is limited by the most frequent
complication of stem cell transplantation: graft-versus-host
disease (GvHD).
Pathogenesis of acute GvHD is explained by the three-
phase model proposed by Ferrara et al. (2009). At first,
tissue damage caused by high-dose chemotherapy and
irradiation (conditioning regimen) induces translocation of
bacterial products (lipopolysaccharides) through gut
mucosa or skin leakage and stimulates proinflammatory
cytokine release: interleukin (IL)-1, IL-6 and tumour
necrosis factor alpha (TNF-α). Thus, host antigen-
presenting cells (APCs) are activated and migrate into
secondary lymphoid organs. In the second phase, activated
host APCs induce proliferation and cytokine production
(IL-2 and interferon gamma, INF-γ) of donor T lympho-
cytes by presenting alloantigens. Furthermore, donor Tcells
differentiate into alloreactive effector T cells against
different alloantigens (minor histocompatibility antigens).
In the last step, two important components mediate
inflammation: cellular effectors like activated alloreactive
effector Tcells and natural killer (NK) cells on the one hand
and soluble inflammatory cytokines as TNF-α, IFN-γ and
IL-1 on the other hand. This in turn causes target cell
apoptosis and thereby enhances alloantigen presentation as
well as cytokine release, thus amplifying and sustaining the
inflammatory reaction.
Acute GvHD occurring within the first months after
transplantation must be differentiated from chronic GvHD,
whose pathophysiology still remains unclear. Depending on
organinvolvement,patientswithacuteGvHDsufferfromskin
rash up to blisters and ulcers, severe diarrhoea and wasting
syndrome or elevated liver enzymes up to liver failure.
However, alloreactive Tcells do not only recognize solid
organtissuelikeskin,gutandliver,butalsoresidualmalignant
cells. This favourable effect named graft-versus-leukaemia
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(Kolb 2008) and is the great benefit of allogeneic transplan-
tation. Therefore, the intention is prevention and treatment of
GvHD while preserving GvL.
GvHD prevention and treatment—preservation of GvL
With regard to epigenetic targets, there are two important
cellular mechanisms: regulatory T cells suppress GvHD
without altering GvL, and NK cells and killer cell
immunoglobulin-like receptors enhance GvL without
inducing GvHD.
Regulatory Tcells—maintenance of (self-) tolerance
Regulatory T cells (Tregs) are known to regulate inflam-
matory response and suppress alloreactive Tcells; the exact
mechanism is unknown so far. They suppress autoimmunity
and GvHD without decreasing GvL (Edinger et al. 2003).
Mice deficient for Tregs usually suffer from autoimmune
diseases, and even in humans, autoimmune disorders are
often accompanied with Tregs dysfunction, e.g. Forkhead
transcription factor Foxp3 gene mutation (Fontenot et al.
2003; Bennett et al. 2001). Recent data suggest that FOXP3
is necessary and essential for sufficient and functional Tregs
that are defined as CD4+CD25+FOXP3+ T cells. The
Foxp3 locus is regulated by epigenetic modifications like
acetylation and methylation (Floess et al. 2007; Tao et al.
2007) and is unmethylated in active Tregs. Regulatory T
cells CD4+CD25+FOXP3+ are mainly generated in the
thymus, but may also arise from naïve CD4+CD25− Tcells
in the periphery by Tcell-receptor stimulation. The number
of circulating Tregs in vivo is low, and purification methods
in vitro still remain inefficient. The ambitious attempt of in
vitro expansion of Tregs also failed so far because of loss of
suppressor function of expanded Tregs possibly due to
inactive Foxp3 (Oliveira et al. 2008). As reported by Floess
et al. (2007) and Tao et al. (2007), FOXP3 expression must
be stabilized by epigenetic modifications such as complete
demethylation of a highly conserved region within the
noncoding region of FOX3 and acetylation of lysine
residues in the forkhead domain by inhibition of HDACs.
Natural killer cells: KIR expression and alloreactivity
NK cells have been shown to have alloreactive potential in the
donor–recipient direction and induce tumour cell lysis without
immune sensitization of the recipient before (Colonna et al.
1993; Ciccone et al. 1992;K i e s s l i n ge ta l .1975). As recently
reviewed by Pegram et al. (2011), NK cell activity is regulated
by inhibitory and activating killer cell immunoglobulin-like
receptors (KIR) whose ligands are major histocompatibility
complex (MHC) class I molecules. If MHC class I ligands for
inhibitory KIR are missing on target cells, NK cells are
activated and mediate cell lysis with preference against
tumour cells. That implies reaction against leukaemia (GvL)
without GvHD. There is evidence that enhanced KIR
mismatch in haploidentical transplantation setting is followed
by an intensified immunological reaction and boosts graft
versus leukaemia effect (Apperley et al. 2008; Ruggeri et al.
2002; Pende et al. 2005).
Epigenetic targets in HSCT
Epigenetic active agents can be divided into two main
groups: histone deacetylase (HDAC) inhibitors like vorino-
stat and panobinostat and DNA methyltransferase
(DNMT) inhibitors like 5-azacytidine and decitabine.
With respect to promising preclinical data, a lot of
translational research still ha st ob ep e r f o r m e dt of u r t h e r
establish these drugs in clinical routine. When used in
the transplantation setting, the potential benefit of HDAC
Table 1 Procedure of allogeneic stem cell transplantation: main phases and principles
Procedure/phase Principle
1 Conditioning regimen
a) Cytoreductive chemotherapy Disease control
Reduction of tumour burden
Induction of remission
b) Myeloablation/immunoablation Elimination of the immune system of the recipient by (high-dose) chemotherapy
or irradiation
2 Stem cell transfusion Donation of “the new” immunosystem
3 Immunosuppression Prevention and treatment of graft rejection and graft-versus-host disease
4 Alloreactivity as further medicinal intervention:
maintenance and relapse therapy
Elimination of residual malignant cells by the graft-versus-leukaemia reaction,
enhancement of the immunotherapeutic effect by donor lymphocyte infusions
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to the main phases of transplantation.
1. Epigenetic agents prior to HSCT
Low disease burden prior to haematopoietic
transplantation is known to come along with
favourable outcome and reduced relapse incidence,
although treatment-related mortality is increased by
pretransplant induction chemotherapy. The benefi-
cial antileukaemic effect of epigenetic active drugs
by activation of silenced genes, derepression of
tumour suppressor genes and induction of differen-
tiation can be used by adding DNMT and HDAC
inhibitors to the conditioning regimen or cytoreductive
chemotherapy.
DNMT inhibitors: decitabine and 5-azacytidine
Treatment with decitabine or 5-azacytidine before or in
combination with common myeloablative or non-
myeloablative conditioning regimen seems to be a
promising approach with respectable results as shown
in several phase I/II studies in mainly pretreated and
refractory AML and MDS patients (De Padua Silva et al.
2007; Lubbert et al. 2006; McCarty et al. 2008;d eL i m ae t
al. 2003;G i r a l te ta l .1997;T a b l e2). Rates of complete
remission prior to transplantation vary from 30% up to
90%, and no unexpected side effects have been reported
(De Padua Silva et al. 2007;d eL i m ae ta l .2003; Fontenot
et al. 2005). Most patients suffer from gastrointestinal
toxicity and neutropenic infection (De Padua Silva et al.
2007). Against previous reports about delayed engraft-
ment after application of hypomethylating agents prior to
transplantation (Giralt et al. 1997), this observation could
not be confirmed in recent studies (De Padua Silva et al.
2007;L u b b e r te ta l .2006; McCarty et al. 2008;d eL i m a
et al. 2003). In conclusion, additional application of
hypomethylating agents prior to transplantation is safe
and might be a favourable option for disease control to
bridge time period to transplant.
HDAC inhibitors
There are no clinical data available for the use of HDAC
inhibitors prior to haematopoietic transplantation so far.
Wang et al. report reduction of myelofibrosis in mice with
JAK2+ primary myelofibrosis (PMF) when PMF cells are
treated sequentially with decitabine and SAHA (vorinostat)
or trichostatin A in vitro prior to transplantation (Wang
et al. 2010). Further investigations are necessary to estimate
a potential benefit of HDAC inhibitors prior to stem cell
transplantation.
2. Epigenetic agents as immunomodulatory therapy
As mentioned above, the clinical goal of stem cell
transplantation is reduction of GvHD while preserving
GvL. Key mechanisms in the treatment of GvHD without
altering GvL effect are regulation of cytokine levels, the
interfering function of regulatory Tcells (Tregs) and the
important role of natural killer (NK) cells.
Promising preclinical data demonstrate the potent
immunomodulatory effect of both HDAC and DNMT
inhibitors in the treatment of GvHD without reducing the
beneficial effect of GvL.
Regulation of cytokine level
Proinflammatory cytokines like TNF-α,I F N - γ, IL-1, IL-6
and IL-12 are essential mediators of GvHD sustaining the
vicious circle of inflammation. HDAC inhibitor vorinostat
(SAHA) has been shown to inhibit the production of
proinflammatory cytokines TNF-α,I F N - γ,I L - 1 β and
IL-12 in lipopolysaccharide-stimulated human peripheral
Table 2 Epigenetic agents prior to HSCT (allogeneic haematopoietic transplantation)
Author n Agent Disease Remission Outcome after
HSCT
[median]
Follow-up
(months)
Reference
Lübbert 2006 10 Dec AML/MDS 40% CR, 10% PR 33% relapse, 33% alive 26/10/1 (Lubbert et al. 2006)
De Padua 2007 12 Dec MDS 33% CR, 50% PR 17% relapse, 75% alive 11.5 (De Padua Silva et al. 2007)
McCarty 2008 25 5-Aza AML/MDS 52% ORR 12 (McCarty et al. 2008)
de Lima 2003 23 Dec 12× AML, 1xCMML,
1× ALL, 9× CML
91% CR 39% relapse, 26% alive 39 (de Lima et al. 2003)
Giralt 1997 4 Dec 3× CML, 1× AMML 2× CR 3× alive 6 (Giralt et al. 1997)
Dec decitabine, 5-Aza 5-azacytidine, AML acute myeloid leukaemia, MDS myelodysplasia, CMML chronic myelomonocytic leukaemia, CML
chronic myeloid leukaemia, ALL acute lymphoblastic leukaemia, AMML acute myelomonocytic leukaemia, CR complete remission, PR partial
remission, ORR overall response rate
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marrow transplantation mouse model, addition of SAHA
day +3 to +7 after transplantation prevents gastrointestinal
tract damage by reducing cytokine release of TNF-α,I F N - γ
and IL-1 in a dose-dependent manner. When compared with
allogeneic controls, mortality and grade of acute GvHD were
reduced corresponding to significantly improved survival
(Reddy et al. 2004). Surprisingly, prophylactic treatment with
SAHA did not alter cytotoxic T cell reaction against host
antigens and thereby preserved GvL effect.
Epigenetic agents boost regulatory Tcells (Tregs)
CD4+CD25+FOXP3+ Tregs are suppressors of autoimmu-
nity and GvHD but do not reduce GvL effect; the exact
mechanism is still not known. The circulating number of
functional Tregs in vivo is limited and effective in vitro
expansion, and purification methods are not available so far.
DNMT inhibitors decitabine and 5-azacytidine as well as
HDAC inhibitors have been reported to be potential
stimulators of Tregs by inducing Foxp3 expression in
CD4+CD25+FOXP3− Tc e l l s .Foxp3 is regulated by
methylation and acetylation and is highly hypermethylated
in nonfunctional Tregs. Treatment of mice with decitabine
and 5-azacytidine after bone marrow transplantation
expands Tregs, enhances the circulating number of func-
tional Tregs by expression of Foxp3 and thereby limits
GvHD without sacrificing GvL (Sanchez-Abarca et al.
2010; Choi et al. 2010). Application of HDAC inhibitors
(trichostatin A, valproic acid and butyrate) in mice provides
similar results (Tao et al. 2007).
DNMT inhibitors and natural killer cells
In clinical trials, treatment with DNMT inhibitors after
haematopoietic stem cell transplantation (HSCT) prevents
relapse and even induces durable remission in relapsed
situation probably by enhancing GvL effect (Giralt et al.
1997; Czibere et al. 2006; Ravandi et al. 2001; Jabbour
et al. 2009;d eL i m ae ta l .2007). NK cells play a key role in
the pathophysiology of graft-versus-leukaemia reaction by
inducing cell lysis with priority against tumour cells. In the
haploidentical transplantation setting, GvL effect is
enhanced by KIR mismatch as mentioned above. Chan et
al. (2003)d e m o n s t r a t e dt h a tKIR expression in NK cells is
regulated by methylation: KIR hypomethylation correlates
with KIR expression. Moreover, treatment of NK cells with
decitabine as methyltransferase (DNMT) inhibitor induces
KIR expression and thereby enhances KIR variability. These
facts suggest that treatment with DNMT inhibitors like
decitabine might induce GvL effect due to tumour cell lysis
by NK cells by enhanced KIR expression and variability.
3. DNMT inhibitors as relapse therapy and maintenance
after HSCT
Patients with leukaemic relapse after stem cell trans-
plantation have a very poor prognosis, and treatment
options are limited because of accumulated toxicity and
impairedorganfunction.DNMTinhibitorsdecitabineand
5-azacytidine have been shown to be effective antileu-
kaemic agents with acceptable toxicity profile that can be
used safely in relapsed situation after HSCT (Giralt et al.
1997; Ravandi et al. 2001; Jabbour et al. 2009)( T a b l e3).
Table 3 Epigenetic agents as relapse therapy after haematopoietic transplantation (HSCT)
Author n Agent Disease Remission Outcome Ref.
Giralt 1997 3 Dec 2× AML, 1× ALL 3× CR 1× relapse, 1× alive (Giralt et al. 1997)
Ravandi 2001 14 Dec+HSCT 9× AML, 2× ALL, 3× CML 8× CR/PR 5× relapse, 5x alive (Ravandi et al. 2001)
Jabbour 2009 9 5-Aza AML 5× CR/PR 1× relapse, 7× alive (Jabbour et al. 2009)
Czibere 2006 6 5-Aza+DLI AML/MDS 3× CR, 2× PR 2× relapse, 2× alive (Czibere et al. 2006)
Decitabine (Dec) and 5-azacytidine (5-Aza) in combination with HSCTor donor lymphocyte infusion (DLI)
AML acute myeloid leukaemia, MDS myelodysplasia, CML chronic myeloid leukaemia, ALL acute lymphoblastic leukaemia, CR complete
remission, PR partial remission
Table 4 5-Azacytidine (5-Aza) as maintenance therapy after haematopoietic transplantation (HSCT)
Author n Agent Disease Duration Outcome Ref.
de Lima 2007 40 5-Aza AML/MDS up to 4 cycles at 28 days 11× relapse (de Lima et al. 2007)
Jabbour 2009 8 5-Aza (+3× HSCT) 7× AML, 1× ALL median 8 cycles á 28 days
(up to 22 cycles)
3 x relapse, 7× alive (Jabbour et al. 2009)
AML acute myeloid leukaemia, MDS myelodysplasia, ALL acute lymphoblastic leukaemia
414 Clin Epigenet (2011) 2:411–416Treatment with 5-azacytidine might even enhance GvL
effect especially in combination with donor lymphocyte
infusions as reported by Czibere et al. (2006). Further-
more, maintenance therapy with 5-azacytidine after stem
cell transplantation might induce durable remission
without increasing acute GvHD (Jabbour et al. 2009;
de Lima et al. 2007; Table 4).
Conclusion
Recent clinical and preclinical data suggest the use of
epigenetic active drugs as a promising new approach in
stem cell transplantation in the 2010s. DNMT and HDAC
inhibitors show high antitumour activity when both used as
additional agents in conditioning regimen and as mainte-
nance therapy or even for remission induction in relapsed
situation after transplantation. When used in heavily pre-
treated patients, the favourable toxicity profile indicates
safety and limited short-term side effects. Long-term side
effects are not known so far. With respect to their impact on
expression pattern of a wide range of genes and function-
ality of proteins, DNMT and HDAC inhibitors might
interfere with different biological mechanisms. Induction
of immunotolerance and anti-inflammation might even
cause higher incidence of malignancies after long-term
treatment. Furthermore, reduction of immune response
might be supposed to result in an increased risk for
opportunistic and other infections. Further studies are
mandatory to evaluate the potential and safety of epigenetic
agents in a higher number of cases.
Preclinical data indicate a beneficial immunomodulatory
effect of DNMT and HDAC inhibitors by enhancing
functional Tregs, regulating inflammatory cytokines and
inducing GvL effect by enhancing KIR expression and
variability of NK cells. Clinical data are still missing so far,
and clinical studies should be investigated to verify the use
of HDAC and DNMT inhibitors for GvHD prophylaxis and
therapy.
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